...strong growth in sales of generics as a result of its November 2010 acquisition of Qualitest Pharmaceuticals...
...from generics rose 131% to $151M and were driven by Endo's November 2010 acquisition of Qualitest Pharmaceuticals...

...3Q10. Sales from generics rose 439% to $148M and were driven by the acquisition of Qualitest Pharmaceuticals...

...He believes the revenue increase largely is driven by the recent acquisition of generics company Qualitest Pharmaceuticals...

...Holdings Inc. sold $400 million in notes to help fund its acquisition of generics play Qualitest Pharmaceuticals...

...billion in cash (see BioCentury, Oct. 4). Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Qualitest Pharmaceuticals...

...The company plans to use the proceeds to partially finance its acquisition of generics company Qualitest Pharmaceuticals...

...The company plans to use the proceeds to partially finance its acquisition of generics company Qualitest Pharmaceuticals...

...company plans to use the proceeds to partially finance its ongoing acquisition of generics company Qualitest Pharmaceuticals...

...advised Endo and J.P. Morgan advised Qualitest. Endo Pharmaceuticals Holding Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Qualitest Pharmaceuticals...

...has secured financing for up to $400 million in order to finance its acquisition of Qualitest Pharmaceuticals. WIR...